The Latest Psychedelics Articles from Streetwise Reports
Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry
Research Report
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report.
Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.
Research Report
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.
Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression
Research Report
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.
Mental Health Co. Hosts Phase II Trials for LSD, Psilocybin
This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics.Showing Results: 1 to 4 of 4